We report a novel phase 2 clinical trial in patients with poor prognosis refractory non-Hodgkin lymphoma (NHL) testing the efficacy of haploidentical donor natural killer (NK) cell therapy (NK dose 0.5-3.27 × 10 7 NK cells/kg) with rituximab and IL-2 (clinicaltrials.gov NCT01181258). Therapy was tolerated without graft-versus-host disease, cytokine release syndrome, or neurotoxicity. Of 14 evaluable patients, 4 had objective responses (29%; 95% CI 12-55%) at 2 months: 2 had complete response lasting 3 and 9 months. Circulating donor NK cells persisted for at least 7 days after infusion at the level 0.6-16 donor NK cells/µl or 0.35-90% of total CD56 cells. Responding patients had lower levels of circulating host-derived Tregs (17 ± 4 vs. 307 ± 152 cells/µL; p = 0.008) and myeloid-derived suppressor cells at baseline (6.6 ± 1.4% vs. 13.0 ± 2.7%; p = 0.06) than non-responding patients. Lower circulating Tregs correlated with low serum levels of IL-10 (R 2 = 0.64; p < 0.003; n = 11), suggestive of less immunosuppressive milieu. Low expression of PD-1 on recipient T cells before therapy was associated with response. Endogenous IL-15 levels were higher in responders than non-responding patients at the day of NK cell infusion (mean ± SEM: 30 ± 4; n = 4 vs. 19.0 ± 4.0 pg/ml; n = 8; p = 0.02) and correlated with day 14 NK cytotoxicity as measured by expression of CD107a (R 2 = 0.74; p = 0.0009; n = 12). In summary, our observations support development of donor NK cellular therapies for advanced NHL as a strategy to overcome chemoresistance. Therapeutic efficacy may be further improved through disruption of the immunosuppressive environment and infusion of exogenous IL-15.
Introduction
Patients with chemotherapy-refractory non-Hodgkin lymphoma (NHL) have poor prognosis [1] . Recent advances in cellular therapies and immunotherapies suggest that targeting tumor with an activated immune system overcomes chemoresistance, and early clinical experience with these approaches has yielded remarkable therapeutic success [2] . Evidence suggests that the immunosuppressive environment surrounding cancer cells contributes to the poor efficacy of therapeutic antibodies and chemotherapy [3] . We hypothesized that natural killer (NK) cells in patients with refractory NHL exhibit poor function with impaired capacity to mediate direct cytotoxic and antibody-mediated killing [4, 5] . NK cells are innate effectors, residing in lymphoid tissues, spleen and peripheral blood at low frequency (5-10% of lymphocytes). Immunophenotypically defined by expression of CD56 and the lack of CD3, NK cells express a variable combination of activating and inhibitory receptors that bind cognate HLA and HLA-independent ligands and exhibit killing of viral-infected or malignant transformed cells with downregulated self-class I MHC [6] . Several known triggers engage NK cells and transform them into powerful cellular killers including cytokines such as IL-2 or IL-15 and antibodies. The most powerful NK cell activating signal is triggered by antibody Fc binding CD16 receptor, which mediates robust target-cell killing with antigen specificity called antibody-dependent cell-mediated cytotoxicity (ADCC) [7] . NK cell killing is either direct (measured by CD107a expression after exposure to target) or mediated by secretion of cytokines such as interferon gamma (IFN-γ) and tumor necrosis factor alpha (TNFα). We hypothesized that infusion of activated allogeneic donor-derived NK cells combined with CD20-targeting monoclonal antibody rituximab and IL-2 would result in anti-tumor responses against lymphoma expressing CD20 and overcome chemotherapy resistance. We report the results of a phase 2 clinical trial testing the efficacy of haploidentical donor NK cell infusions plus rituximab for refractory NHL.
Patients and methods

Eligibility criteria and treatment
We conducted a prospective clinical trial approved by the Institutional Review Board (IRB) of the University of Minnesota (clinicaltrials.gov NCT01181258). Eligible patients had multiple relapsed or refractory NHL or chronic lymphocytic leukemia expressing CD20, Karnofsky performance status (KPS) ≥ 80%, and adequate organ function. All patients were evaluated by positron emission tomography (PET) within 4 weeks of treatment and at 2 months post-NK cell infusion. We confirmed CD20 expression by immunohistochemistry on tumor biopsy at the time of last relapse or at the time of enrollment. Treatment consisted of lymphodepleting chemotherapy pentostatin 3.75 mg × 2 days, (n = 6), cyclophosphamide (60 mg/kg IV day − 5; n = 6) and IL-2 receptor-targeting agent to deplete regulatory T cells (Treg) denileukin diftitox (18 μg/kg/day IV day − 1; n = 5). We prospectively planned to increase the dose of denileukin diftitox to 18 μg/kg/day IV × 3 days (day − 4, − 3, − 2) for lack of Treg depletion (defined as no increase in Treg at day 14 compared to pre-therapy) in first 5 patients. After we enrolled 1 more patient, denileukin was withdrawn from the market (and our study) by the manufacturer (Eisai). We subsequently amended the protocol and replaced the lymphodepleting therapy with fludarabine 25 mg/m 2 × 4 days (n = 10), cyclophosphamide (60 mg/kg IV day − 5; n = 10) and methylprednisolone (1 mg/kg day − 2 through day + 9; n = 10) with the aim to enhance NK cell function (Supplementary Figure 1 ). All patients received rituximab 375 mg/ m 2 IV weekly × 4 doses starting day − 8. The NK-enriched cellular product was infused intravenously on day 0 followed by subcutaneous infusion of IL-2 at 9 million IU every other day × 6 doses.
Cellular product and NK cell evaluation
Donor selection criteria included HLA-haploidenticalrelated donor aged 12-75 years who is able and willing to undergo leukapheresis. We preferred younger donors if multiple were available. HLA-haploidentical-related donors underwent 5-h lymphapheresis with COBE Spectra Apheresis System (TerumoBCT, Lakewood, CO, USA). Apheresis product was depleted of T cells (CD3) and B cells (CD19) using the Miltenyi Biotec CliniMACS® Cell Selection System and CD3 and CD19 MicroBeads and reagent (Miltenyi Biotec, Auburn, CA, USA) and cultured in serum-free media (X-VIVO 15, Cambrex BioScience, Walkersville, MD, USA) supplemented with 10% human AB serum and 1000 U/mL IL-2 (Chiron Corporation, Emeryville, CA, USA) [8] . After 8-16 h of incubation, cells were washed twice with a 5% human serum albumin. An aliquot of the cell product was analyzed by flow cytometry to determine the number of T, B, and NK cells, and NK cell phenotype (fluorochromeconjugated antibodies detailed in Supplementary Table 1) . The planned target NK cell dose to be infused was between 1.5 and 8 × 10 7 /kg. Lot release criteria for allogeneic IL-2-activated NK cell product (BB-IND 8847) included viability > 70%, NK cell (CD56 + CD3−) >20%, T cell content ≤ 3.0 × 10 5 /kg, B cell content < 3%, endotoxin < 5EU/kg and no organism by Gram stain. If product contained less then 1.5 × 10 7 kg or < 20% NK cells, than all cells were given but NK expansion outcome was reported separately. In vivo circulating peripheral blood (PB) donor-derived NK cells were examined in fresh samples in all evaluable patients and enumerated as absolute lymphocyte count/μL × % CD56 + / CD3 − NK cells (in lymphocyte gate) × % whole blood donor chimerism using standard very short tandem repeat (VNTR) testing from the whole blood. In recipient-donor pairs differentially expressing HLA-A2 or HLA-A24 antigens, we performed peripheral blood (PB) flow cytometry analyzing donor-specific HLA alleles to quantify the donor NK cells. For each recipient, we determined panel reactive antibody (PRA) by Flow/Luminex assay: flow bead immunoassays utilized purified antigen coated on latex beads as targets for binding of specific antibody in human serum. PRA was correlated with the level of donor NK cell expansion and clinical response.
Sample collection for correlative studies
We collected PB at baseline, after chemotherapy, and on days 3, 7, 14, and 28. We processed mononuclear cells (PBMC) by Ficoll method and stored cells in liquid nitrogen and serum at − 80 °C. For comparison, we also obtained PB from healthy volunteers and newly diagnosed patients with NHL prior to receiving any therapy. All volunteer subjects and patients signed an IRB-approved consent for study of their PB samples.
Flow cytometry analysis and ELISA
Cryopreserved PBMCs were rested overnight in RPMI medium to recover from freezing and then cultured for 6 h in the presence of target cells (K562) and IL-12 (5 ng/ ml) and IL-18 (50 ng/ml) prior to staining. Cells were stained with fluorochrome-conjugated antibodies detailed in Supplementary 
Study definitions and statistical methods
The primary objective of the prospective trial was overall response rate at 2 months. Secondary objectives were safety and tolerability of this therapy and in vivo expansion of allogeneic NK cells. All patients were evaluated by positron emission tomography/computed tomography (PET/CT) and bone marrow biopsy (if prior marrow involvement) per recent criteria for NHL [9] . Trial size calculation was based on Simon method using a minimax two-stage design with early stopping rule if less than 20% of patients achieve an objective response and a 50% response was a rate worthy of further study. The maximum sample size of 17 patients was sufficient to maintain an overall type I error of 5% while providing 80% statistical power. The first enrollment included 6 patients with an early stop if 2 or fewer patients respond. With January 2012, revision of the preparative regimen removed denileukin diftitox (taken off the market by Eisai) and added low-dose methylprednisolone (1 mg/kg days − 2 to + 9); stage 1 enrollment was restarted. Response in < 6 patients or <25% of patients achieve NK cell expansion was considered not worthy of further study. Cell frequencies were summarized using descriptive statistics. Statistical analysis was performed using a paired or unpaired Student t test and Pearson correlation (Graphpad Prism, version 6; ElCamino, CA). p values from secondary endpoints were subject to multiple comparison adjustment using the falsediscovery rate (FDR) [10] . A p value < 0.05 (raw p value and FDR) was considered statistically significant. Representative histograms or images were chosen based on average values ± SEM.
Results
Patient, disease and product characteristics
Sixteen patients were enrolled in the study (Table 1) between 10/19/2010 and 7/9/2015. Patients had a median age of 52 years (range 48-67) and 13 were males. Diffuse large B cell lymphoma was the most common diagnosis (n = 11; 5 1 3 transformed and 6 de novo). All patients were rituximab and chemotherapy refractory and failed at least 3 prior therapies. Most patients had B-symptoms and extranodal disease at the time of treatment. The cellular product was infused with a median total nuclear cell (TNC) dose of 4.3 × 10 7 /kg (range 1.9-7.7) and contained 40.2% NK cells (median; range 12-88%) and 48% monocytes (median, range 12-63%). The final product characteristics are detailed in Table 1 . Clinical product NK cell characteristics included high expression of CD16 (median 86%) and high cytotoxicity against K562 targets. Final product NK cells produced higher IFNγ, and had higher proliferation compared to before activation (Supplementary Figure 2a ). Expression of NKp44, NKp46, CD69, TIGIT and PD1 on the activated NK product and NK cell inhibitory receptor expression are detailed in Supplementary  Figure 2 and Supplementary Table 2 .
Clinical response assessment
Clinical outcomes are summarized in /kg, less than the planned target cell dose).
We observed expected hematologic toxicity (NCI) common terminology criteria for adverse events (CTCAE) grade 1-3 thrombocytopenia, anemia and neutropenia in all subjects. Therapy was associated with NCI CTCAE non-hematologic grade 3 adverse effects (tumor lysis syndrome, infection due pneumocystis; Clostridium difficile colitis, neutropenic fever, thrombotic microangiopathy related to pentostatin). Two patients (out of 16) died before disease response assessment: one developed sepsis prior to NK cell infusion, and the second died of overwhelming culture-negative sepsis 10 days after NK cell infusion, both deaths are possibly attributed to study therapy. IL-6 levels at day 7 in all 15 patients varied from 3.99 to 21.5 pg/ml; these levels did not suggest cytokine release syndrome. We observed no symptoms or signs of graft-versus-host disease, neurotoxicity, or persistent marrow aplasia.
NK cells in patients with refractory NHL are hypofunctional
As compared to healthy controls, NK cells in patients with newly diagnosed NHL (not enrolled to this trial) and chemorefractory NHL (all enrolled to this trial) exhibited poor degranulation capacity (CD107a) and impaired production of pro-apoptotic cytokines IFNγ (Fig. 1a) . Moreover, the expression of CD16, which mediates ADCC, was lowest in patients with refractory NHL (Fig. 1a) . NK cells from patients with NHL expressed higher levels of the suppressive receptor "T cell immunoreceptor with Ig and ITIM domains" (TIGIT) and lower levels of the T cell immunoglobulin mucin-3 (TIM-3) receptor with activating function on NK cells compared to healthy controls (Fig. 1b) [11] [12] [13] . NK cell expression of programmed cell death 1 receptor (PD1) was below 2% in patients and controls.
Transient donor NK cell persistence and function correlated with endogenous IL-15
We determined the frequency of circulating donor NK cells at defined time points by two methods designed to differentiate recipient vs. donor by interrogating DNA (VNTR) or HLA expression (flow cytometry). Donor NK cells persisted in the PB for at least a week after infusion (in 7 of 7 tested patients with available antibodies against donorspecific HLA alleles) ranging between 0.6 and 16 cells/µl (median 3 cells/µl), and 0.35-90% of PB NK cells exhibited a donor-specific HLA phenotype (Fig. 2a) . We separately analyzed 3 patients infused with < 1.5 × 10 7 TNC/kg (outside of lot release criteria goal) and determined that all 3 had evidence of donor cells by HLA-specific immunophenotype (Patients 3, 5, 7). Donor-derived NK cells exhibited higher CD16 expression compared with patients' NK cell CD16 (mean MFI ± SEM: 9900 ± 1460 vs. 3590 ± 740, p = 0.002, FDR = 0.007 Fig. 2b) . Whole blood VNTR detected donor DNA in 3 patients out of 14 tested samples at day 7 at levels 2, 8, 18% donor chimerism, suggesting lower sensitivity as compared to HLA allele-directed flow cytometry. In one responding patient, donor NK cells were sustained beyond day 28 (3% on DNA chimerism by VNTR). Although not significant, NK cells proliferated more vigorously in responders as compared to non-responders (day 14: Ki67 mean ± SEM: 45.1 ± 7.0, n = 4 vs. 28.5 ± 4.6, n = 10; p = 0.07, FDR = 0.01; Fig. 3a) ; yet, PB NK cell function as measured by CD107, IFNγ, and TNFα was similar in responders and non-responders at baseline and after treatment (Supplementary Figure 3) . Endogenous IL-15 serum levels peaked at the time of NK cell infusion (range 11-33 pg/dl). Responders had higher IL-15 levels as compared to non-responders at day 0 (mean ± SEM: 30.0 ± 4.0 (n = 4) vs 19.0 ± 4.0 pg/ml (n = 8); p = 0.02, FDR = 0.04) but not day 14 post-chemotherapy (10.5 ± 6.0 (n = 4) vs 4 ± 2 pg/ ml (n = 8; p = NS) (Fig. 3b) . Serum IL-15 levels correlated with functional NK cell killing at day 14 as measured by expression of CD107a (R 2 = 0.74; p = 0.0009, FDR = 0.006 (adjusted slope); n = 12, Fig. 3c ), suggesting that higher endogenous IL-15 improved NK cell cytotoxic capacity. We next examined the effect of pre-existing recipient anti-HLA antibodies on donor NK cells' persistence. Fifteen recipients were tested at baseline and 2 patients had high-level donor HLA allele-specific antibodies. Both patients with high titer PRA exhibited donor NK cell expansion at day 7 (10 and 6 NK cells/µL) and one was a responder, suggesting lack of an adverse effect of PRA on NK cell persistence and clinical outcomes.
High expression of PD-1 and TIGIT correlates with lack of response
We next examined T cells from the NHL patients and random healthy donors for expression of key inhibitory checkpoints: programmed cell death receptor 1 (PD-1) and T cell immunoreceptor with Ig and ITIM domains (TIGIT) at baseline and at day 14 post-therapy. Responding patients had similar levels of PD-1 expression to healthy controls at baseline and day 14; however, non-responders exhibited significantly higher levels of PD-1 on T cells before and particularly after therapy. Similarly, T cell TIGIT expression was higher in non-responders at both time points (Fig. 4a, b) . Separating PB T cells into CD3 + CD4 + and CD3 + CD8 + , we observed a higher pattern of PD-1 and TIGIT expression on CD3 + CD4 + cells and CD8 + T effectors in non-responders as compared to responders (Fig. 4b) .
Low Treg and myeloid suppressor cell levels correlate with response
We next examined the impact of immune suppressor cells on NK cell expansion and clinical response. Responding patients (n = 4) had lower levels of absolute number of Treg at baseline (mean ± SEM: 17 ± 4 vs. 307 ± 152 cells/µL; p = 0.008, FDR = 0.02) and 14 days after therapy (53 ± 21 vs. 273 ± 63 cells/µL; p = 0.02, FDR = 0.04) as compared to non-responders (n = 8) (Fig. 5a ). Treatment with denileukin diftitox did not result in change in PB Treg frequency (day 14 Treg with denileukin mean ± SEM: 240 ± 56 cells/µL vs. no denileukin 160 ± 90) and had no effect on in vivo NK cell expansion (data not shown). High PB Treg levels correlated with serum IL-10 (R 2 = 0.7; p < 0.0001, FDR = 0.001; n = 12) and IL-2 receptor-α (IL-2Rα R 2 = 0.4; p = 0.006, FDR = 0.02; n = 12), suggestive of an accentuated immunosuppressive milieu. Although not statistically significant, frequencies of PB myeloid-derived suppressor cells (MDSC) were low in responders and higher in non-responders at baseline (mean ± SEM: 6.6 ± 1.4% vs. 13 ± 2.7%) and after therapy (day 14 mean ± SEM: 4.8 ± 0.7%; vs. 10.0 ± 2.0%; Fig. 5b) . Notably, low levels of circulating Tregs and MDSCs correlated with NK cell proliferation (n = 12, R 2 = 0.25; p = 0.035, FDR = 0.054 and R 2 = 0.5; p = 0.002, FDR = 0.007; Fig. 5c, d ).
Discussion
Our clinical experience using haploidentical NK cells with IL-2 and rituximab suggests that this therapy is well tolerated and produces remission in over 1/4th of highly refractory NHL patients. We showed a transient persistence of donor NK cells in most subjects and improved sensitivity + CD3 − cells. All 7 subjects with differentiating donor/recipient HLA antigens (A2 or A24) are shown. Patients 1, 2 and 3 were responders; patients 4, 5 and 6 were nonresponders and patient 7 died from neutropenic sepsis at day 10 after NK cell infusion. Absolute lymphocyte cell (ALC) in cells/µL and whole blood standard very short tandem repeat (WB VNTR) at day 7 after NK cell infusion is shown for each patient. b Donors' and recipients' CD16 expression 7 days following infusion are shown as mean ± SEM, and statistical analysis were done on pooled data using the Student's unpaired t test 1 3 of donor NK detection by flow cytometry for donor-specific DNA as compared to PCR techniques. Our data also show that autologous NK cells in refractory NHL patients exhibited poor function, express lower CD16, higher levels of the immunosuppressive receptor TIGIT and lower expression of activating receptor TIM3 as compared to NK cells from healthy controls. These findings suggest several potential mechanisms of immunotherapy resistance in patients with advanced disease. Monoclonal antibodies are often used to focus autologous NK cells to have tumor specificity; however, CD16 downregulation can render antibodies less effective. We showed that transient homeostatic expansion of highly functional CD16 expressing donor NK cells may be clinically effective in some refractory NHL patients.
While prior data demonstrated that the tumor microenvironment plays an important role in disease severity and clinical outcomes in B cell NHL, most studies examined the composition of intratumoral T cells, whereas here, we probed the blood compartment [14] [15] [16] . T cell exhaustion is a status of T cell immune response induced by viral infection or tumor which results in reduced function and proliferation [15] . Our findings suggest that refractory NHL patients have a highly suppressive immune environment characterized by increased expression of PD-1 and TIGIT on circulating T cells. In contrast, low baseline expression of PD-1 and TIGIT on CD8 cells and lower Tregs in the blood compartment was associated with improved clinical responses to adoptive NK cell transfer. Together, these findings highlight the role of the immunosuppressive milieu in modulating an anti-tumor response. TIGIT is a novel key inhibitory checkpoint protein expressed on both NK and T cells with wide variation in its expression among individuals [17, 18] . Nonresponding patients had elevated expression of TIGIT on T cells. Interestingly, we found increased levels of TIGIT in CD8 cells and marked decreased levels in CD4 T cells following treatment in non-responding patients. In line with our data, earlier studies have shown that tumor-engaged CD8 T cells have increased TIGIT, which is associated with exhaustion and poor clinical responses in acute myeloid leukemia (AML) patients, while CD4 T cell TIGIT expression did not correlate with clinical responses [19] . Our findings suggest that blockade of checkpoint proteins could enhance efficacy of NK cell adoptive therapies and potentially elicit higher clinical response rates in refractory NHL [4] . Recent in vitro report suggested that the blockade of the TIGIT pathway can increase NK cell IFNγ secretion and abrogate MDSCmediated inhibition [20] .
In this clinical trial, we showed no benefit of denileukin on Treg depletion, NK cell persistence or clinical response. Notably, three responders received methylprednisone as part of their therapysuggesting that the effect of steroids in adoptive NK cell therapy may not be detrimental. Our prior experience showed lack of consistent Treg depletion by denileukin [21] ; yet, we observed significantly improved response rates in refractory AML, which did not occur in our NHL cohort. Given the relatively small number of treated patients with denileukin in this trial (due to withdrawal of denileukin from the market), our study was not powered to compare the two therapeutic approaches.
In terms of the product characteristics, NK cell-enriched product contained variable fraction of other cells, mostly monocytes that likely contributed to in vivo cytokine production such as IL-15, IL-18, IL-6, TNF, and IL-10 [22, 23] . Our prior data suggested that using CD56 positively selected NK cell products produced lower remission rate in AML compared to CD19/CD3-depleted products [21] . Many pre-clinical and clinical investigations continue to study the impact of NK cell dose, purity and expansion on in vivo NK cell persistence and clinical outcomes [24] [25] [26] [27] [28] [29] . The size of this trial had limited statistical power to examine the effect of killer cell immunoglobulin-like receptor (KIR) genotype or KIR ligand mismatch on clinical outcomes.
Taken together, our observations allowed identification of host factors that may have interfered with response to adoptive NK cell infusion. We showed that high frequencies of MDSCs were associated with lack of clinical response. These data are concordant with pre-clinical results that showed that MDSCs mediate potent inhibition of conventional NK cells [30, 31] . In addition, increased numbers of MDSC have been detected in patients with diffuse large B cell lymphoma at diagnosis and correlated with worse outcomes [32, 33] . Furthermore, tumor infiltrating MDSC have been recognized to recruit Treg cells and be permissive of further tumor growth [34] . In our study, circulating Treg appears to limit NK cell proliferation. We suggest that MDSCs and Treg should be studied in future trials as cellular biomarkers of resistance to adoptive NK cell therapy. These findings also highlight the possibility of targeting MSDCs to enhance the efficacy of cellular therapies [35] . In this study we also confirmed the importance of endogenous cytokines released after lymphodepleting chemotherapy. Levels of IL-15 in PB after chemotherapy and prior NK cell infusion were almost twofold higher in patients who experienced clinical response. This finding supports the development of therapeutic cytokines, such as recombinant human IL-15 (NCI) or IL-15 superagonist ALT803 (Altor), in combination with NK cells to further improve clinical activity. Pilot clinical studies with NK cell therapies are underway (NCT03050216).
Our observation supports development of donor NK cellular therapies for advanced NHL as a treatment strategy. NK cell expansion and therapeutic efficacy might be further improved by checkpoint inhibitors, MDSC-depleting strategies, and IL-15 administration. 
